Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Abbott

Applying Vibrotactile Stimulation to Improve Parkinson’s

Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson's community catalyzed the founding of Charco and how #innovative medical devices and software can improve...

Impetus Digital

Applying Vibrotactile Stimulation to Improve Parkinson’s

Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson's community catalyzed the founding of Charco and how #innovative medical devices and software can improve...

Impetus Digital

Cannes Lion 2022

Our Top 5 Pharma Picks From Cannes Lions

Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022.

The Good Ideas Group

Applying Vibrotactile Stimulation to Improve Parkinson’s

Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson's community catalyzed the founding of Charco and how innovative medical devices and software can improve...

Impetus Digital

- PMLiVE

OPEN Health continued support for My Name’5 Doddie

Charity fundraising for Motor Neuron Disease

OPEN Health

The ALS patient journey

Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...

Blue Latitude Health

- PMLiVE

Intec sounds a sad note as Accordion Parkinson’s trial fails

Intec’s lifeline now is Novartis partnership

- PMLiVE

AmyPore gets EU backing for Alzheimer’s and Parkinson’s therapy

Novel chimeric peptide ready to start clinical trials

- PMLiVE

Abbott’s wearable glucose monitor to be available across England

FreeStyle Libre will be prescribed to those with T1 diabetes

- PMLiVE

Theranexus takes Alzheimer’s drug combo into clinic

150-subject phase 1b trial to start at eight centres in France

- PMLiVE

AbbVie’s uterine fibroids drug aces second phase III trial

An FDA verdict is expected in the US in the coming weeks

- PMLiVE

Smart watch epilepsy monitor cleared by FDA

Approval could potentially clear the way for insurers to reimburse its cost

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links